China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
IRVINE, Calif., April 27, 2017 -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces that it will release financial results for the three months ended March 31, 2017 after market close on Thursday, May 4, 2017. CombiMatrix management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
| Live Call: | U.S.: | (866) 634-2258 |
| International: | (330) 863-3454 | |
| Live Webcast: | http://investor.combimatrix.com/events.cfm The webcast replay will be archived for 30 days | |
| Replay: | U.S.: | (855) 859-2056 |
| International: | (404) 537-3406 | |
| Passcode: | 10856966 | |
| The telephone replay will be available for seven days |
About CombiMatrix Corporation
CombiMatrix Corporation provides best-in-class molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. Our testing focuses on advanced technologies, including single nucleotide polymorphism chromosomal microarray analysis, next-generation sequencing, fluorescent in situ hybridization and high resolution karyotyping. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.
Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation (949) 753-0624 Investor Contact: LHA Jody Cain (310) 691-7100 [email protected]
